Abstract:Bisphosphonate‐induced lymphatic drainage impairment exacerbates bone necrosis. Zoledronate acid triggers endoplasmic reticulum stress and apoptosis in lymphatic endothelial cells via the NAD+/SIRT6/XBP1s pathway. Novel nanoparticle‐loaded Zoledronate acid and rapamycin enhances autophagy, restores lymphatic function, and mitigates bisphosphonates‐related osteonecrosis of the jaw progression. Background Bisphosphonates (BPs) are the first‐line treatment to stop bone resorption in diseases, including osteoporosis, Paget's disease, multiple myeloma and bone metastases of cancer. However, BPs‐related osteonecrosis of the jaw (BRONJ), characterized by local inflammation and jawbone necrosis, is a severe intractable complication. The cumulative inflammatory burden often accompanies impaired lymphatic drainage, but its specific impact on BRONJ and the underlying mechanisms remain unclear. Methods The mouse BRONJ model was established to assess the integrity and drainage function of lymphatic vessels by tissue clearing techniques, injected indocyanine green lymphatic clearance assay, flow cytometry analysis and histopathological staining. RNA sequencing, metabolome analysis, transmission electron microscopy and Western blotting were utilized to analyze the impacts of Zoledronate acid (ZA) on endoplasmic reticulum stress (ERS) and function of lymphatic endothelial cells (LECs). By constructing Lyve1creERT; SIRT6f/f and Lyve1creERT; ATG5f/f mice, we evaluated the role of ERS‐induced LECs apoptosis in the progression of BRONJ. Additionally, we developed a nanoparticle‐loaded ZA and rapamycin (ZDPR) to enhance autophagy and evaluated its potential in mitigating BRONJ. Results The mouse BRONJ model displayed impaired lymphatic drainage, accompanied by significant local inflammation and bone necrosis. The prolonged stimulation of ZA resulted in the extension of ERS and the inhibition of autophagy in LECs, ultimately leading to apoptosis. Mechanistically, ZA activated XBP1s through the NAD+/SIRT6 pathway, initiating ERS‐induced apoptosis in LECs. The conditional knockout mouse models demonstrated that the deletion of SIRT6 or ATG5 significantly worsened lymphatic drainage and inflammatory infiltration in BRONJ. Additionally, the innovative nanoparticle ZDPR alleviated ERS‐apoptosis in LECs and enhanced lymphatic function, facilitating inflammation resolution. Conclusion Our study has elucidated the role of the NAD+/SIRT6/XBP1s pathway in ERS‐induced apoptosis in ZA‐treated LECs, and further confirmed the therapeutic potential of ZDPR in restoring endothelial function and improving lymphatic drainage, thereby effectively mitigating BRONJ. Key points Bisphosphonate‐induced lymphatic drainage impairment exacerbates bone necrosis. Zoledronate acid triggers endoplasmic reticulum stress and apoptosis in lymphatic endothelial cells via the NAD+/SIRT6/XBP1s pathway. Novel nanoparticle‐loaded Zoledronate acid and rapamycin enhances autophagy, restores lymphatic function, and mitigates bisphosphonates‐related osteonecrosis of the jaw progression.

Targeting endoplasmic reticulum stress‐induced lymphatic dysfunction for mitigating bisphosphonate‐related osteonecrosis

Zoledronic Acid Accelerates ER Stress-Mediated Inflammation by Increasing PDE4B Expression in Bisphosphonate-Related Osteonecrosis of the Jaw

Skeletal Site-specific Effects of Zoledronate on in vivo Bone Remodeling and in vitro BMSCs Osteogenic Activity

Dietary nitrate improves jaw bone remodelling in zoledronate-treated mice

Functionalized DNA Nanomaterials Targeting Toll‐Like Receptor 4 Prevent Bisphosphonate‐Related Osteonecrosis of the Jaw via Regulating Mitochondrial Homeostasis in Macrophages

Revival of nitrogen-containing bisphosphonate-induced inhibition of osteoclastogenesis and osteoclast function by water-soluble microfibrous borate glass

Intravenous Transplantation of Apoptosis Repressor with Caspase Recruitment Domain-Overexpressing Mesenchymal Stem Cells Promotes Bone Formation in Bisphosphonate-Related Osteonecrosis of the Jaw Rats

Study on the Pathogenesis of Bisphosphonate-related Osteonecrosis of the Jaw in Rats

Zoledronic Acid Regulates the Synthesis and Secretion of IL-1β Through Histone Methylation in Macrophages

Zoledronate Induces Autophagic Cell Death in Human Umbilical Vein Endothelial Cells Via Beclin-1 Dependent Pathway Activation

Cell-based Immunotherapy with Mesenchymal Stem Cells Cures Bisphosphonate-Related Osteonecrosis of the Jaw-Like Disease in Mice.

Anti-inflammatory effect of polydeoxyribonucleotide on zoledronic acid-pretreated and lipopolysaccharide-stimulated RAW 264.7 cells

Beta-adrenergic receptor antagonist propranolol prevents bisphosphonate-related osteonecrosis of the jaw by promoting osteogenesis

Predictors of BRONJ in High-Risk Cancer Patients

Zoledronate Attenuates Angiogenic Effects Of Angiotensin Ii-Stimulated Endothelial Progenitor Cells Via Rhoa And Mapk Signaling

Zoledronic acid promotes osteoclasts ferroptosis by inhibiting FBXO9-mediated p53 ubiquitination and degradation

Low-level laser therapy prevents medication-related osteonecrosis of the jaw-like lesions via IL-1RA-mediated primary gingival wound healing

Systemic administration of quality- and quantity-controlled PBMNCs reduces bisphosphonate-related osteonecrosis of jaw-like lesions in mice

Small Extracellular Vesicles Derived from Adipose Tissue Prevent Bisphosphonate-Related Osteonecrosis of the Jaw by Promoting Angiogenesis

[The role of semaphorin 4D in the mechanism of bisphosphonate-related osteonecrosis of the jaw in rats]

Photobiomodulation Can Prevent Medication-Related Osteonecrosis of the Jaw Formation in Tooth Extraction Site of Rat Model